An Open-Label, Multicenter, Nonrandomized, Dose-Escalation, and Tumor-Expansion Phase 1/2 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat (INCB024360), With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 08 Nov 2018
At a glance
- Drugs CB 1158 (Primary) ; Epacadostat (Primary) ; Pembrolizumab
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Incyte Corporation
- 29 Oct 2018 Planned End Date changed from 17 Nov 2018 to 31 Jan 2019.
- 26 Jun 2018 Planned End Date changed from 21 Feb 2021 to 17 Nov 2018.
- 26 Jun 2018 Status changed from recruiting to active, no longer recruiting.